GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Organovo Holdings Inc (NAS:ONVO) » Definitions » Cyclically Adjusted Price-to-FCF

Organovo Holdings (Organovo Holdings) Cyclically Adjusted Price-to-FCF : (As of Jun. 12, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Organovo Holdings Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Organovo Holdings Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Organovo Holdings's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organovo Holdings Cyclically Adjusted Price-to-FCF Chart

Organovo Holdings Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Organovo Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Organovo Holdings's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Organovo Holdings's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organovo Holdings's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Organovo Holdings's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Organovo Holdings's Cyclically Adjusted Price-to-FCF falls into.



Organovo Holdings Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Organovo Holdings's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Organovo Holdings's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.266/131.7762*131.7762
=-0.266

Current CPI (Mar. 2024) = 131.7762.

Organovo Holdings Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.921 100.560 -1.207
201409 -1.685 100.428 -2.211
201412 -1.144 99.070 -1.522
201503 -1.547 99.621 -2.046
201506 -1.790 100.684 -2.343
201509 -1.965 100.392 -2.579
201512 -1.532 99.792 -2.023
201603 -1.760 100.470 -2.308
201606 -1.851 101.688 -2.399
201609 -1.461 101.861 -1.890
201612 -1.514 101.863 -1.959
201703 -1.442 102.862 -1.847
201706 -2.051 103.349 -2.615
201709 -1.165 104.136 -1.474
201712 -1.207 104.011 -1.529
201803 -1.039 105.290 -1.300
201806 -1.260 106.317 -1.562
201809 -0.759 106.507 -0.939
201812 -0.680 105.998 -0.845
201903 -0.849 107.251 -1.043
201906 -0.936 108.070 -1.141
201909 -0.791 108.329 -0.962
201912 -0.089 108.420 -0.108
202003 -0.492 108.902 -0.595
202006 -0.394 108.767 -0.477
202009 -1.089 109.815 -1.307
202012 -0.217 109.897 -0.260
202103 -0.276 111.754 -0.325
202106 -0.185 114.631 -0.213
202109 -0.250 115.734 -0.285
202112 -0.401 117.630 -0.449
202203 -0.183 121.301 -0.199
202206 -0.286 125.017 -0.301
202209 -0.268 125.227 -0.282
202212 -0.354 125.222 -0.373
202303 -0.562 127.348 -0.582
202306 -0.611 128.729 -0.625
202309 -0.364 129.860 -0.369
202312 -0.386 129.419 -0.393
202403 -0.266 131.776 -0.266

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Organovo Holdings  (NAS:ONVO) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Organovo Holdings Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Organovo Holdings's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Organovo Holdings (Organovo Holdings) Business Description

Industry
Traded in Other Exchanges
Address
11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels.
Executives
David Gobel director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Vaidehi Joshi director C/O ORGANOVO HOLDINGS, INC., 11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Alison Tjosvold Milhous director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Adam K Stern director STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Thomas Hess officer: President, CFO and PFO 366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Douglas Jay Cohen director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Thomas E Jurgensen officer: General Counsel & Secretary 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Jeffrey N. Miner officer: Chief Scientific Officer 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Chris Heberlig officer: President and CFO C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Keith Murphy director, officer: Executive Chairman 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Steven George Hughes officer: Chief Medical Officer 6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Carolyn Beaver director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David Shapiro director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Presnell Sharon Collins officer: EVP, Research & Development 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Taylor Crouch director, officer: CEO & President 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075